Frontiers in nephrology最新文献

{"title":"The impact of SLCO1B1 polymorphisms on homocysteine concentrations: evidence for a stronger association in men.","authors":"Xinyuan Hu, Yanfang Jiang","doi":"10.3389/fneph.2024.1465380","DOIUrl":"10.3389/fneph.2024.1465380","url":null,"abstract":"<p><strong>Background: </strong>Homocysteine (Hcy) is a risk factor for stroke. In this study, we investigated the relationship between gene polymorphisms, particularly SLCO1B1 and homocysteine (Hcy) concentrations in ischemic stroke patients, with a focus on identifying potential risk factors for elevated Hcy levels.</p><p><strong>Methods: </strong>A total of 177 ischemic stroke patients, including 99 with single nucleotide polymorphisms (SNPs), underwent pharmacogenomics (PGx) sequencing tests, from September 2022 to November 2023 at the hospital. Logistic regression analysis was used to analyze the relationship between clinical characteristics, SNPs, and Hcy concentrations. In the sub-study, 207 ischemic stroke and 244 non-stroke patients underwent SLCO1B1c.521T>C polymorphism to further demonstrate the role of SLCO1B1c.521T>C polymorphism and homocysteine.</p><p><strong>Results: </strong>Higher Hcy concentrations were observed in men compared to women. Univariate logistic analysis identified gender, GGT concentrations, B12 concentrations, folic acid concentrations, and SLCO1B1 c.521 CC+CT polymorphism as risk factors for elevated Hcy. Multivariate logistic analysis confirmed that B12 concentrations, folic acid concentrations, and SLCO1B1 CT + CC polymorphism were significant dependent risk factors. In the sub-study, SLCO1B1 CT + CC polymorphism and the male sex were identified as risk factors for Hcy, with the effect of SLCO1B1 polymorphism being more pronounced in men.</p><p><strong>Conclusion: </strong>Folic acid and vitamin B12 reduce Hcy concentrations, while the SLCO1B1 CT and CC polymorphisms are associated with higher Hcy levels. The impact of SLCO1B1 gene polymorphism on Hcy is notably stronger in the male population, suggesting that genetic factors play a significant role in determining Hcy levels.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1465380"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global and national public awareness and interest in glomerular diseases from 2004 to 2024.","authors":"Suryanarayanan Balakrishnan, Charat Thongprayoon, Iasmina M Craici, Wisit Cheungpasitporn, Jing Miao","doi":"10.3389/fneph.2025.1519481","DOIUrl":"10.3389/fneph.2025.1519481","url":null,"abstract":"<p><strong>Background: </strong>Glomerular diseases significantly impact global health. This study investigated public interest in five common glomerular diseases.</p><p><strong>Methods: </strong>Google Trends™ were used to analyze search activity from January 2004 to December 2024 for IgA nephropathy (IgAN), membranous glomerulonephritis (MN), focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and diabetic nephropathy (DN). Data were retrieved both globally and in English-speaking countries, including the United States. Monthly and yearly relative search activity were assessed and compared.</p><p><strong>Results: </strong>Globally, IgAN had the highest average relative search activity, followed by DN, FSGS, LN, and MN. Both IgAN and FSGS exhibited declining trends, while LN showed an upward pattern. MN and DN experienced a modest decline before 2016, preceded by a slight increase. Among English-speaking countries, search interest was predominantly concentrated in five countries, primarily including the United States, United Kingdom, Canada, and Australia, with the United States consistently ranking as the leading country. For IgAN, LN, and MN, the trends observed in the United States appeared to align with global data. In contrast, search interest for FSGS exceeded global levels, while interest in DN was slightly lower than global activity. In the United States, IgAN, FSGS, and LN were most prominent in North Dakota, Massachusetts, and Delaware, respectively, while DN and MN saw peak activity in West Virginia.</p><p><strong>Conclusion: </strong>Public engagement with glomerular diseases has not uniformly grown, at least in English-speaking countries, emphasizing the need for enhanced awareness efforts. Future analysis should prioritize search terms in the predominant language of each country.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"5 ","pages":"1519481"},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of donor eGFR and HLA-DR mismatch on graft survival in living donor kidney transplants.","authors":"Pooja Budhiraja, Jesse D Schold, Rocio Lopez, Susana Arrigain, Bruce Kaplan","doi":"10.3389/fneph.2024.1518791","DOIUrl":"10.3389/fneph.2024.1518791","url":null,"abstract":"<p><strong>Background: </strong>This study assesses the impact of human leukocyte antigen (HLA)-DR mismatch and donor-estimated glomerular filtration rate (eGFR) on outcomes of living donor kidney transplantation (LDKT), which are especially relevant to the availability of multiple donors and paired kidney exchanges.</p><p><strong>Methods: </strong>Using data from the Scientific Registry of Transplant Recipients (SRTR), we retrospectively analyzed graft survival in adult LDKT recipients transplanted between January 2013 and September 2022. Recipients with 0 HLA-DR mismatches were compared to those with 1-2 HLA-DR mismatches. Cox models assessed the association between donor eGFR and graft and patient survival, stratifying by a) HLA-DR mismatches, and b) HLA-DR mismatches and recipient age.</p><p><strong>Results: </strong>Among 44,080 recipients, 7,195 had 0 HLA-DR mismatches and 36,885 had 1-2 HLA-DR mismatches. The recipients' mean age was 49.1 for the 0 HLA-DR mismatch group and 50.4 for the 1-2 HLA-DR mismatch group. The donors' mean age was 43.1 and 43.8, with an eGFR of 101.0 and 99.9 ml/min, respectively. A higher donor eGFR was associated with better graft survival. Stratified analyses showed higher donor eGFR levels reduced the risk of graft loss in cases with DR mismatch (p < 0.001) but not in cases without HLA-DR mismatch (p = 0.81). This effect was significant for recipients aged 18-39 and over 60. Similar results were observed for patient survival.</p><p><strong>Conclusions: </strong>Higher donor eGFR was associated with lower risks of graft loss and patient death in the HLA-DR mismatch group but not the 0 HLA-DR mismatch group. These results emphasize the importance of considering both HLA-DR matching and donor kidney function, particularly for younger recipients to avoid sensitization for future transplants.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1518791"},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urine kidney injury molecule-1 predicts subclinical kidney disease among persons living with HIV initiating tenofovir disoproxil fumarate-based ART in Zambia.","authors":"Freeman W Chabala, Edward D Siew, C William Wester, Alana T Brennan, Masauso M Phiri, Michael J Vinikoor, Sepiso K Masenga, Muktar H Aliyu","doi":"10.3389/fneph.2024.1468409","DOIUrl":"10.3389/fneph.2024.1468409","url":null,"abstract":"<p><strong>Introduction: </strong>Antiretroviral therapy (ART) increases the life expectancy of persons living with HIV (PLWH), but not without potentially serious adverse effects. Tenofovir disoproxil fumarate (TDF) can cause nephrotoxicity, manifesting as acute kidney injury (AKI) that may persist after treatment discontinuation. Kidney injury biomarkers such as kidney injury molecule-1 (KIM-1), retinol-binding protein-4 (RBP-4), interleukin-18 (IL-18), and neutrophil gelatinase-associated lipocalin (NGAL) can aid early diagnosis and predict TDF-associated nephrotoxicity. This study aimed to determine whether the change from baseline in urine KIM-1 (δKIM-1) and NGAL (δNGAL) following 2 weeks of TDF use could predict subclinical TDF-associated nephrotoxicity before the overt manifestation as acute kidney disease after 3 months.</p><p><strong>Methods: </strong>A prospective cohort study of 205 PLWH was conducted at the Adult Center for Infectious Disease Research (AIDC) in Lusaka, Zambia. ART-naïve PLWH who were starting treatment with TDF with intact kidney function [estimated glomerular filtration rate (eGFR)> 60 mL/min/1.73m²] were followed at initiation, 2 weeks, and approximately 3 months to determine the incidence of TDF-associated nephrotoxicity. We measured urine KIM-1 and NGAL at baseline and after 2 weeks of treatment to determine if it predicted subclinical nephrotoxicity. The presence of TDF-associated nephrotoxicity was defined according to the established acute kidney disease and disorders criteria (AKD) as having either 1) one or more episodes of eGFR< 60ml/min/1.73m² within 3 months, 2) a reduction in eGFR of greater than 35% (from baseline) within 3 months, and/or 3) an increase in serum creatinine of more than 50% (from baseline) within 3 months.</p><p><strong>Results: </strong>The incidence of TDF-associated nephrotoxicity was 22%. Baseline eGFR, creatinine, age, female sex, and BMI predicted the risk of overt TDF-associated nephrotoxicity. The median baseline KIM-1-to-creatinine and NGAL-1-to-creatinine ratios of the participants who developed overt TDF-associated nephrotoxicity and those who did not were not significantly different. However, every 1 pg/mg increase in δKIM-1 was associated with a 41% higher risk of TDF-associated nephrotoxicity. No association was observed with δNGAL.</p><p><strong>Conclusions: </strong>The incidence of TDF-associated nephrotoxicity was high. Change in KIM-1 level within 2 weeks of the initiation of TDF treatment predicted subclinical TDF-associated nephrotoxicity before overt manifestation as acute kidney disease while δNGAL within the same period did not predict subclinical TDF-associated nephrotoxicity.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1468409"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular injury in glomerulopathies: the role of the endothelium.","authors":"Géssica Sabrine Braga Barbosa, Niels Olsen Saraiva Câmara, Felipe Lourenço Ledesma, Amaro Nunes Duarte Neto, Cristiane Bitencourt Dias","doi":"10.3389/fneph.2024.1396588","DOIUrl":"10.3389/fneph.2024.1396588","url":null,"abstract":"<p><p>In glomerulopathies, endothelial dysfunction and the presence of histological vascular lesions such as thrombotic microangiopathy, arteriolar hyalinosis, and arteriosclerosis are related to a severe clinical course and worse renal prognosis. The endothelial cell, which naturally has anti-inflammatory and anti-thrombotic regulatory mechanisms, is particularly susceptible to damage caused by various etiologies and can become dysfunctional due to direct/indirect injury or a deficiency of protective factors. In addition, endothelial regulation and protection involve participation of the complement system, factors related to angiogenesis, the renin-angiotensin system (RAS), endothelin, the glycocalyx, the coagulation cascade, interaction between these pathways, interactions between glomerular structures (the endothelium, mesangium, podocyte, and basement membrane) and interstitial structures (tubules, arterioles and small vessels). Dysregulation of those components is also associated with the progression of renal fibrosis, since endothelial cell damage promotes endothelial-to-mesenchymal transition. Although the potential mechanisms of vascular injury have been widely described in diabetic kidney disease, hypertensive nephrosclerosis, and hemolytic uremic syndrome, they require further elucidation in other glomerulopathies. A better understanding of the pathogenesis of vascular injury in patients with glomerular diseases could contribute to the development of specific treatments for such injury.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1396588"},"PeriodicalIF":0.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Insights in glomerular disease.","authors":"Bryan Chang, Abbal Koirala, Duvuru Geetha","doi":"10.3389/fneph.2024.1480968","DOIUrl":"10.3389/fneph.2024.1480968","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1480968"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage.","authors":"Bernard Canaud, Peter Stenvinkel, Rebecca Scheiwe, Sonja Steppan, Sudhir Bowry, Giuseppe Castellano","doi":"10.3389/fneph.2024.1455321","DOIUrl":"10.3389/fneph.2024.1455321","url":null,"abstract":"<p><p>In hemodialysis (HD), complement activation, bioincompatibility, and inflammation are intricately intertwined. In the 1970s, as HD became a routine therapy, the observation of complement pathway activation and transient leukopenia by cellulosic dialysis membranes triggered the bioincompatibility debate and its clinical relevance. Extensive deliberations have covered definitions, assessment markers, scope, and long-term clinical consequences of membrane-dependent bioincompatibility reactions. While complement pathways' interplay with coagulation and inflammation has been delineated, HD's focus has primarily been on developing more biocompatible membranes using advanced technologies. Recent advances and understanding of the current HD delivery mode (4-hour sessions, thrice weekly) suggest that factors beyond membrane characteristics play a significant role, and a more complex, multifactorial picture of bioincompatibility is emerging. Chronic activation of the complement system and persistent low-grade \"uremic inflammation\" in chronic kidney disease (CKD) and HD lead to premature inflammaging of the kidney, resembling aging in the general population. Cellular senescence, modulated by complement activation and the uremic milieu, contributes to chronic inflammaging. Additionally, the formation of neutrophil extracellular traps (NETs, process of NETosis) during HD and their biological activity in the interdialytic period can lead to dialysis-induced systemic stress. Thus, complement-inflammation manifestations in HD therapies extend beyond traditional membrane-related bioincompatibility consequences. Recent scientific knowledge is reshaping strategies to mitigate detrimental consequences of bioincompatibility, both technologically and in HD therapy delivery modes, to improve dialysis patient outcomes.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1455321"},"PeriodicalIF":0.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review.","authors":"Thomas S van Lieshout, Anastasia K Klerks, Osman Mahic, Robin W M Vernooij, Michele F Eisenga, Brigit C van Jaarsveld, Alferso C Abrahams","doi":"10.3389/fneph.2024.1488758","DOIUrl":"10.3389/fneph.2024.1488758","url":null,"abstract":"<p><strong>Background: </strong>Patients with kidney failure undergoing dialysis often suffer from anemia. Iron deficiency, along with a shortage in erythropoietin, is a common cause. Peritoneal dialysis (PD) patients may have a different iron metabolism compared to hemodialysis (HD) patients. This study aims to compare both dialysis modalities regarding their differences in iron management.</p><p><strong>Methods: </strong>PubMed (MEDLINE) and Embase were screened for randomized controlled trials and observational studies including both patients on HD or PD with information on iron management. Outcomes for iron management for this systematic review included: prevalence of supplementation, route of administration, dose, frequency and hemoglobin and iron status parameters.</p><p><strong>Results: </strong>15 eligible studies (930,436 patients), of which 8 cohort and 7 cross-sectional, were analyzed. The prevalence of intravenous (IV) iron supplementation ranged from 11.7% to 84.4% in HD patients, compared to 1.6% to 49.0% in PD patients. Ten studies reported that HD patients only received IV iron, while five studies reported this for PD patients. For oral iron supplementation, three studies involved HD patients, whereas seven studies involved PD patients. The cumulative monthly IV iron dose ranged from 108 to 750 mg in the HD group, compared to 65 to 250 mg in the PD group. Hemoglobin levels ranged from 10.0 to 12.0 g/dL in HD patients, versus 9.6 to 11.9 g/dL in PD patients.</p><p><strong>Conclusion: </strong>Iron management differs between HD and PD patients, with HD patients receiving higher doses and more frequent IV iron. There was significant heterogeneity in the outcomes between the studies, primarily due to the lack of a uniform global policy on iron management. Despite these differences, hemoglobin levels and iron status parameters were comparable between the two groups. Future research should explore the underlying mechanisms and broader impacts of iron treatment, including patient-reported outcomes, to optimize anemia management and improve quality of life for dialysis patients.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42022336970.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1488758"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing body composition in living kidney donors: impact on post-transplant kidney function.","authors":"Evelien E Quint, Lisa B Westenberg, Gertrude J Nieuwenhuijs-Moeke, Eva A N van den Broek, Marcel Zorgdrager, Alain R Viddeleer, Stephan J L Bakker, Ija M Nolte, Marco van Londen, Robert A Pol","doi":"10.3389/fneph.2024.1467669","DOIUrl":"10.3389/fneph.2024.1467669","url":null,"abstract":"<p><p>Living donor kidney transplantation boasts superior patient and graft survival rates compared to deceased donor kidney transplantation. However, the impact of living donor body composition (BC) on post-transplant kidney function remains uncertain. In a cohort of 293 living kidney donor-recipients pairs, we utilized linear mixed model analyses, adjusted for time and including a multiplicative interaction term of time with the donor body composition measure, and found no significant associations between any donor BC measure and the annual change in recipient post-transplantation estimated glomerular filtration rate (eGFR) [donor body mass index (BMI): <i>B</i>=-0.01, 95%CI -0.13; 0.11, <i>p</i>=0.88; donor waist circumference: <i>B</i>=0.02, 95%CI -0.02; 0.06, <i>p</i>=0.38; donor skeletal muscle index: <i>B</i>=-0.02, 95%CI -0.07; 0.04, <i>p</i>=0.63; donor skeletal muscle radiation attenuation: <i>B</i>=-0.002, 95%CI -0.06; 0.06, <i>p</i>=0.96; donor visceral adipose tissue index: <i>B</i>=-0.001, 95%CI -0.02; 0.02, <i>p</i>=0.93; donor subcutaneous adipose tissue index: <i>B</i>=-0.001, 95%CI -0.02; 0.02, <i>p</i>=0.94; donor intramuscular adipose tissue index: <i>B</i>=-0.12, 95%CI -0.29; 0.06, <i>p</i>=0.19; donor total abdominal adipose tissue index: <i>B</i>=-0.001, 95%CI -0.01; 0.01, <i>p</i>=0.89]. Our study suggests that pre-donation BC does not affect post-transplantation recipient eGFR in donor populations with a BMI below 35 kg/m².</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1467669"},"PeriodicalIF":0.0,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible benefits for environmental sustainability of combined therapy with hemodialysis and peritoneal dialysis in Japan.","authors":"Kei Nagai","doi":"10.3389/fneph.2024.1394200","DOIUrl":"10.3389/fneph.2024.1394200","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"4 ","pages":"1394200"},"PeriodicalIF":0.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}